Do Multidisciplinary Team (MDT) processes influence survival in patients with colorectal cancer? A population-based experience by unknown
RESEARCH ARTICLE Open Access
Do Multidisciplinary Team (MDT) processes
influence survival in patients with colorectal
cancer? A population-based experience
Alastair Munro1*, Mhari Brown2, Paddy Niblock1, Robert Steele3 and Frank Carey4
Abstract
Background: MDT (multidisciplinary team) meetings are considered an essential component of care for patients
with cancer. However there is remarkably little direct evidence that such meetings improve outcomes. We assessed
whether or not MDT (multidisciplinary team) processes influenced survival in a cohort of patients with colorectal cancer.
Methods: Observational study of a population-based cohort of 586 consecutive patients with colorectal cancer
diagnosed in Tayside (Scotland) during 2006 and 2007.
Results: Recommendations from MDT meetings were implemented in 411/586 (70.1 %) of patients, the MDT+ group.
The remaining175/586 (29.9 %) were either never discussed at an MDT, or recommendations were not implemented,
MDT- group. The 5-year cause-specific survival (CSS) rates were 63.1 % (MDT+) and 48.2 % (MDT-), p < 0.0001. In analysis
confined to patients who survived >6 weeks after diagnosis, the rates were 63.2 % (MDT+) and 57.7 % (MDT-), p = 0.064.
The adjusted hazard rate (HR) for death from colorectal cancer was 0.73 (0.53 to 1.00, p = 0.047) in the MDT+ group
compared to the MDT- group, in patients surviving >6 weeks the adjusted HR was 1.00 (0.70 to 1.42, p = 0.987). Any
benefit from the MDT process was largely confined to patients with advanced disease: adjusted HR (early) 1.32 (0.69 to
2.49, p = 0.401); adjusted HR(advanced) 0.65 (0.45 to 0.96, p = 0.031).
Conclusions: Adequate MDT processes are associated with improved survival for patients with colorectal cancer.
However, some of this effect may be more apparent than real – simply reflecting selection bias. The MDT process
predominantly benefits the 40 % of patients who present with advanced disease and conveys little demonstrable
advantage to patients with early tumours. These results call into question the current belief that all new patients with
colorectal cancer should be discussed at an MDT meeting.
Background
The introduction of routine Multidisciplinary Team
(MDT) meetings into cancer care in the UK followed
the publication of the Calman-Hine Report [1]. The as-
sumption was that regular MDT meetings, at which all
new patients with cancer would be discussed, would be
an effective method of extending the benefits of “special-
ist care” [2] (however that might be defined) to all pa-
tients with cancer. By 2000, the National Cancer Plan [3]
contained the instruction: “from 2001 put in place site-
specific multidisciplinary teams and ensure all patients
are reviewed by them”. The assumption was that the
MDT process would improve survival rates for patient
with cancer in the UK.
There are now over 200 publications assessing, or
claiming to assess, the benefits associated with MDT
meetings (“tumor boards” in the USA) for patients
with cancer. These papers range across a wide variety
of tumour types, however only six papers [4–9] de-
scribe the effect of MDT discussion upon survival in
patients with colorectal cancer. Their main features
are summarised in Table 1. Given the relative paucity
of available evidence, we have reviewed the effect of
MDT discussion, and implementation of recommen-
dations, on survival in a population-based cohort of
patients with colorectal cancer who were diagnosed in* Correspondence: a.j.munro@dundee.ac.uk
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Table 1 Details of studies on the relationship between MDT discussion and outcome in patients with colorectal cancer
Author Country Setting Period Patients Comparison Factors significant in MVA Survival outcome HR death any cause
(95 % c.i.)
Ye China Hospital-based 1999–2006 after radical resection for
colorectal cancer
before MDT introduced in
2002 (n = 297) cf. after MDT (n = 298)
MDT, Age, Differentiation,
Number of nodes examined,
Stage
OS 0.62 (0.46 to 1.48)
Du China Hospital-based 2001–2005 with resectable locally
advanced rectal cancer
contemporaneous patients; n = 101
were evaluated by MDT members
and were treated with neoadjuvant




OS, DFS 0.88 (0.52 to 1.48)
Lordan England Hospital-based 1996–2006 with hepatic metastases
from colorectal cancer
who were referred for
liver surgery
those who were referred by a team
which contained a HPB surgeon
(n = 108); those who were referred




referral via team with HPB
surgeon, macroscopic invasion
of diaphragm
OS, DFS 0.85 (0.60 to 1.19)
McDermid Scotland Surgeon-based 1997–2005 with resected colorectal
cancers (excluding Dukes’A)
before MDT introduced in 2002
(n = 176) cf. after MDT (n = 134)
Age, stage, MDT OS 0.73 (0.54 to 0.99)
Palmer Sweden Regional 1995–2004 with rectal cancer invading
into adjacent organs
3 groups 1) n = 65 discussed at MDT
appropriately staged 2) n = 99
appropriately staged not discussed
at MDT 3) n = 139 not appropriately
staged (whether or not discussed at
MDT)
Age OS (CSS for MVA) 0.95 (0.62 to 1.45)
Wille-Jorgensen Denmark Hospital 2001–2006 Rectal cancer Before MDT introduced (n = 467)
c.f.after MDT introduced (n = 344)
No MVA OS 0.94 (0.79 to 1.12)
OS Overall Survival, DFS Disease-free Survival, CSS Cause-specific survival, MVA Multivariate Analysis, EMVI Extramural vascular invasion, HPB Hepatobiliary, CEA Carcinoembryonic antigen, HR Hazard ratio (event is death












2006 and 2007, and for whom we have data from
long-term follow-up.
Methods
We performed a retrospective review of prospectively
acquired data. Tayside is a geographically defined re-
gion of Eastern Scotland. Since 1997 there has been a
weekly colorectal MDT meeting at which all newly
diagnosed patients within the region are discussed.
All pathology, including that from the very few pri-
vate patients, is discussed at the MDT. The informa-
tion we have gathered reflects a regional, population-
based, experience.
All patients in Tayside have a unique identification
number (the CHI number) which can be used to link
individual patient’s records across multiple databases.
We used hospital information systems to obtain infor-
mation on all patients with a diagnosis of colorectal
cancer in Tayside between 1st January 2006 and 31st
December 2007 this approach has been approved by
the Caldicott Guardian and the Tayside Regional Eth-
ics Committee (REC reference 06/S1402/3). This pro-
ject was classified as clinical audit and therefore
written informed consent from patients was not re-
quired. The data analysed in this study are not pub-
licly available.
We obtained data on MDT discussions and recom-
mendations from worksheets filled in by senior clinicians
(PN, AM) at each MDT meeting. We accepted the fol-
lowing as definitions of “recommendation”: surgery;
radiotherapy; chemotherapy; neoadjuvant therapy; for
oncological opinion; for further investigation; palliative
care; follow-up only. Each patient, rather than each dis-
cussion, was the unit of analysis.
We staged patients using the TNM system (5th edi-
tion) [10] from which we generated Dukes’ stage; we
scored co-morbidity using the ACE-27 system [11].
Linkage via postcode provided information on income
deprivation using Scottish Index of Multiple Deprivation
(SIMD) data from 2006 [12]. Using hospital notes, radi-
ology information systems, oncology electronic patient
records, and other hospital-based documentation, we
assessed whether or not the initial recommendation
made by the MDT had, or had not, been implemented.
Data on outcomes came from the electronic patient re-
cords and central hospital information systems. We en-
tered the anonymised data into a FileMaker Pro database
(FileMaker Inc.) and exported the data to Stata (Stata-
Corp) for statistical analyses.
Statistical analyses included: Fisher’s exact test for
tabular comparisons; Mann–Whitney test for com-
parison of group means; the Kaplan-Meier method
for constructing survival curves; the logrank test for
comparison of survival curves; Cox’s proportional
hazards model for multivariate analysis of prognostic
factors.
Results
We identified 586 patients (311 males; 275 females)
newly diagnosed with colorectal cancer between 1st
January 2006 and 31st December 2007: 337 patients have
died; 230 from colorectal cancer and 107 from other
causes. The surviving patients have been followed up for
a median of 74 months (range 16 to 91; mean 73.3). Of
the 586 patients, 513 were discussed at an MDT meeting.
For the majority of patients discussed at MDT meetings
there was clear evidence of a definite recommendation be-
ing made: for only 31/513 (6.0 %) of discussions was it
impossible to identify a recommendation. The MDT rec-
ommendation was implemented in 411/586 (70.1 %) of
patients; the recommendation was not implemented in
102/586 (17.4 %) of patients and 73/586 (12.5 %) of
patients were never discussed at an MDT. For simplicity
of analysis, we have merged the group who were never
discussed with the group who were discussed, but in
whom the MDT recommendation was not implemented:
the MDT process could contribute little, if anything, to
outcomes for these patients.
Table 2 summarises the demographic and clinical
characteristics of the patients according to two groups:
MDT+ (discussed at an MDT with evidence of an imple-
mented recommendation); MDT- (either not discussed
or no implemented recommendation). The groups dif-
fered significantly in age, stage, histological grade and
comorbidity. There were no significant differences in
gender, tumour site, or income deprivation.
Figure 1 illustrates the routes followed by patients
following initial diagnosis. We partitioned the analysis
according to whether or not patients survived more
than 6 weeks after the date of diagnosis. This is be-
cause patients who die soon after diagnosis may not
be discussed in the MDT and this could artefactually
lower survival rates in the group of patients defined
as “not discussed”. Forty five patients died within six
weeks of diagnosis: their mean age was 77.7 years
(range 55 to 91; median 79); 22 were female and 23
were male; 31 had advanced or metastatic disease, 14
had early disease; 28 died from rapidly progressive
disease, 11 died from complications following surgery
and 6 died from co-morbid conditions. Only 4 of
these 45 patients (8.9 %) were in the MDT+ group,
41/45 (91.1 %) were in the MDT- group.
Overall survival at 5 years was significantly better in
the MDT+ group, 52.2 % (95 % confidence interval 47.3
to 56.7 %), than in the MDT- group, 33.6 % (95 % confi-
dence interval 26.7 to 40.6 %); logrank p value <0.00001.
The hazard ratio adjusted for age, gender, stage, tumour
site, grade, socioeconomic deprivation and co-morbidity
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was 0.72 (95 % confidence interval 0.56 to 0.92; p =
0.009) for the MDT+ group compared with the MDT-
group.
The 5-year cause-specific survival (CSS) for the
MDT+ group was 63.1 % (95 % confidence interval 58.0
to 67.8 %); for the MDT- group the rate was 48.2 % (95 %
confidence interval 40.2 to 55.8 %). This difference was
statistically significant: p value by logrank test < 0.00001.
The corresponding survival curves are shown in Fig. 2. In
analysis confined to patients surviving for more than
6 weeks after diagnosis the cause-specific survival rates at
5 years are: MDT+ group 63.2 % (95 % confidence interval
58.1 to 67.9 %); for the MDT- group the rate was 57.7 %
(95 % confidence interval 48.6 to 65.7 %). This difference
was not statistically significant: p value by logrank test =
0.064.
In univariate analysis the hazard ratio (HR) for
death from colorectal cancer was 0.53 (95 % confi-
dence interval 0.40 to 0.69; p < 0.0001) when patients
in the MDT+ group were compared with those in the
Table 2 Clinico-pathological variables according to group – p values are from Fisher’s exact test and Mann–Whitney test. Staging is
according to the Dukes’ system
Total MDT+ MDT- P value
Mean age 70.6 (69.6 to 71.6) 68.6 (67.4 to 69.8) 75.3 (73.7 to 76.9) <0.0001
Gender N N N
Female 275 46.9 % 191 46.5 % 84 48.0 % 0.786
Male 311 53.1 % 220 53.5 % 91 52.0 %
Stage
Early or A or B 213 36.3 % 148 36.0 % 65 37.1 % <0.0001
C 135 23.0 % 112 27.3 % 23 13.1 %
Neoadjuvant 38 6.5 % 35 8.5 % 3 1.7 %
Advanced or metastatic 200 34.1 % 116 28.2 % 84 48.0 %
Grade
Well or moderate 427 72.9 % 320 77.9 % 107 61.1 % <0.0001
Poor 87 14.9 % 65 15.8 % 22 12.6 %
Unknown 49 8.4 % 23 5.6 % 26 14.9 %
No histology 23 3.9 % 3 0.7 % 20 11.4 %
Site
Right colon 200 34.1 % 137 33.3 % 63 36.0 % 0.785
Left colon 196 33.5 % 140 34.1 % 56 32.0 %
Rectum 174 29.7 % 124 30.2 % 50 28.6 %
Unspecified 16 2.7 % 10 2.4 % 6 3.4 %
Income deprivation quintile
Least deprived 114 19.5 % 79 19.2 % 35 20.0 % 0.889
2nd 151 25.8 % 107 26.0 % 44 25.1 %
3rd 123 21.0 % 91 22.1 % 32 18.3 %
4th 94 16.0 % 64 15.6 % 30 17.1 %
Most deprived 81 13.8 % 55 13.4 % 26 14.9 %
Unknown 23 3.9 % 15 3.7 % 8 4.6 %
ACE-27 comorbidity score
0 162 27.7 % 132 32.1 % 30 17.1 % <0.0001
1 201 34.3 % 151 36.7 % 50 28.6 %
2 93 15.9 % 59 14.4 % 34 19.4 %
3 53 9.0 % 31 7.5 % 22 12.6 %
Unknown 77 13.1 % 38 9.3 % 39 22.3 %
Total 586 100.0 % 411 70.1 % 175 29.9 %
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MDT- group. This effect was attenuated by adjust-
ment (for age, gender, tumour stage, tumour site,
tumour grade, income deprivation and comorbidity)
in multivariate analysis: HR 0.73 (95 % confidence
interval 0.53 to 1.00; p = 0.047). The corresponding
figures, considering only those patients who survived
for more than 6 weeks, were: univariate HR 0.75
(95 % confidence interval 0.55 to 1.01; p = 0.065); ad-
justed HR 1.00 (95 % confidence interval 0.70 to 1.42;
p = 0.987).
We further divided the patients, according to stage
at presentation into two main groups: 386 patients
with operable or early disease (T1-4Nx,0-2M0) – the
“early” group; 200 patients with locally advanced (in-
operable) or metastatic disease (TunknownNunknownM0;
TanyNanyM1) – the “advanced” group. The 5 year
cause-specific survival for the patients with advanced
disease was 14.3 %; for the patients with early disease
it was 81.8 %. Figure 3 shows the cause-specific sur-
vival curves for early and advanced patients. The sur-
vival rates and adjusted hazard ratios are summarised
in Table 3.
Only three patients were apparently denied the oppor-
tunity for adjuvant treatment because they were not
Fig. 1 Flow chart illustrating the population of patients and outcomes
Fig. 2 Kaplan-Meier survival curves for cause-specific survival according to MDT group
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discussed at an MDT. One is alive with no evidence of dis-
ease at 6.5 years, one died of an unrelated cause 2.8 years
after diagnosis, and one patient died from rectal cancer
11 months after diagnosis. Despite the lack of MDT dis-
cussion, this patient was reviewed post-operatively in the
oncology department. When seen and assessed the patient
had diarrhoea and weight loss following a colo-anal anas-
tomosis: the patient was not considered sufficiently fit for
adjuvant chemotherapy, her disease later recurred and she
was treated with palliative radiotherapy.
Fig. 3 Kaplan-Meier cause-specific survival curves according to extent of disease (for definition see text) and MDT group
Table 3 Five year Cause-specific survival (CSS) rates with p values from logrank test. The hazard ratios (HR) their 95 % confidence
intervals and associated p values were estimated using the Cox proportional hazards model with adjustment for age, gender, grade
and site of tumour, income deprivation, co-morbidity and, where appropriate, stage. The MDT+ group is compared to the
MDT- group and so a hazard rate <1.00 indicates survival benefit from MDT discussion and implementation
5 year CSS Logrank p Adjusted HR p value
All patients MDT+ MDT-
All stages 63.1 % 48.2 % <0.0001 0.73 (0.53 to 1.00) 0.047
Early 80.6 % 86.4 % 0.598 1.32 (0.69 to 2.49) 0.401
Advanced 18.0 % 8.4 % <0.00001 0.65 (0.45 to 0.96) 0.031
Survived >6w
All stages 63.2 % 57.7 % 0.064 1.00 (0.70 to 1.42) 0.987
Early 80.6 % 90.6 % 0.138 1.85 (0.88 to 3.88) 0.105
Advanced 18.2 % 11.8 % 0.064 0.89 (0.58 to 1.36) 0.590
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Discussion
Main points
We present here a population-based approach to the
question of whether or not colorectal MDT meetings
improve survival in patients with colorectal cancer.
These results reflect those achieved by a mature MDT, a
group of clinicians who had been working together for
over eight years. We have included comorbidity and
socio-economic deprivation as well as other more widely
reported demographic and clinico-pathological variables
in our analysis. We found no evidence that patients with
potentially curable tumours suffer harm as a result of
failure in the MDT process. There is some apparent
benefit from MDT discussion in patients with advanced
or metastatic disease, but the evidence is insufficient to
determine whether this is an artefact arising from selec-
tion bias or whether the advantage is genuine. The stat-
istical treatment of deaths within six weeks of diagnosis
had an important effect on the estimate of the magni-
tude of the effect associated with the MDT process.
Censoring deaths occurring within six weeks of diagno-
sis attenuated the estimated benefit: mainly because only
a small proportion (<10 %) of patients who died within
6 weeks had evidence of an implemented MDT recom-
mendation. This is important for two reasons. Firstly, it
is unlikely that the MDT process could, per se, have had
any influence over the occurrence of these early deaths.
Secondly, including these patients, whose fates were
largely sealed by the time of diagnosis, introduces a se-
lection bias which will exaggerate the perceived benefits
associated with the MDT process.
Limitations
This is an observational study and, as such, is subject to
bias. The group of patients (MDT-) who were not dis-
cussed at an MDT meeting, or where MDT recommen-
dations were not implemented, was not derived through
random allocation, and it is highly likely that member-
ship of this group was influenced by confounding vari-
ables not considered in the analysis. Although nearly
600 patients are included in this study, there are only
175 patients in the MDT- group and so statistical com-
parisons may be relatively underpowered.
We adopted a loose definition of what constituted a
“recommendation”. We did not stipulate that the MDT
had to define a specific plan for treatment and accepted
that, bearing in mind that patients themselves may not
have been adequately represented at the MDT [13], it is
reasonable to consider that further discussion with an
oncologist could constitute an outcome.
By using cause-specific survival as the outcome of inter-
est for the study, we excluded consideration of whether
MDT discussion might have had an impact on the
morbidity of treatment by, for example, recommending
rectum-conserving surgery rather than abdomino-perineal
excision. However, the prime purpose behind the intro-
duction of MDT meetings was to improve survival and
this is therefore the standard by which the process should
be judged.
These patients were assessed and managed in the pre-
biological era of treatment for colorectal cancer. All pa-
tients had access to standard chemotherapeutic agents
and to conformally-planned radiotherapy. However, at
the time of initial decision-making, biological agents
(such as cetuximab and bevacizumab) had not been ap-
proved for use in Scotland. Pathological specimens were
not routinely assessed for molecular markers – primarily
because no targeted agents were available for treatment.
Strengths
This is a population-based study and the results and
conclusions may therefore have more general relevance
than those from studies based on data from a single hos-
pital. We have complete follow-up, including details of
vital status, for all patients. We have been able to docu-
ment not just whether the patient was discussed at an
MDT meeting, or whether a recommendation was made,
but also whether or not any recommendation was imple-
mented. The analysis covers a short time period, only
two years, and all patients were cared for by the same
team of oncologists and surgeons. There is therefore
consistency of decision-making and clinical management.
General discussion
There is a dramatic difference in long-term survival
when the experience of patients with early disease is
compared with that of patients who present with ad-
vanced or metastatic disease: the 5 year survival for the
200 patients with advanced disease was 14.3 %, the cor-
responding figure for the 386 patients with early disease
was 81.8 %. The magnitude of this difference may go
some way to explaining the observed differences in colo-
rectal survival when comparisons are made between in-
stitutions, or amongst nations [14]. Any underreporting
or exclusion of patients with advanced or metastatic dis-
ease will significantly inflate the overall estimates of sur-
vival after a diagnosis of colorectal cancer.
We have presented results for all patients, and for that
subset of patients who survived for at least six weeks
after diagnosis. By excluding patients who died within
six weeks of diagnosis we eliminate from consideration
patients who presented as emergencies and who died
within a few weeks of surgery, as well as those patients
who presented in the terminal phase of their illness. It is
unreasonable to expect that MDT discussion would im-
prove outcomes for such patients, their fates are deter-
mined by events that are usually beyond the control of
any MDT.
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When survival analysis was restricted to patients who
survived for at least six weeks after diagnosis any bene-
fits associated with MDT discussion were less evident.
This suggests that, in a population-based series such as
this one, MDT discussion is to some extent an indicator
of longer-term survival. Patients who die at and around
the time of diagnosis are less likely to be discussed at an
MDT meeting. This is consistent with the finding that
MDT discussion and implementation of recommenda-
tions was less likely in patients with higher levels of co-
morbidity (Table 2).
Our results are consistent with the published literature
[4–9] in patients with colorectal cancer: the MDT
process is associated with improved survival. However,
we clearly demonstrate that in patients with non-
metastatic disease the MDT process contributes little to
cancer-specific survival (Fig. 3 and Table 3). The appar-
ent benefit of the MDT discussion is most marked in
patients with advanced disease. This benefit is still ap-
parent, although not statistically significant, when those
patients who die within six weeks of diagnosis are ex-
cluded from analysis. This suggests that the main contribu-
tion of the MDT may be to co-ordinate the management
of patients with complex clinical problems – potentially
resectable liver metastases, tumours of borderline operabil-
ity. Clinicians are not always aware of what their colleagues
in other specialties might have to offer [15]. A recent
Australian study [16] looking at the effect of MDT discus-
sion upon management decisions drew similar conclusions.
MDT discussions were of more value for patients with
more complex clinical problems. Of course it is entirely
possible that the observation of benefit in this group is due
to hidden confounding – only those patients who, on a
priori grounds, are expected to benefit are discussed, the
others are not. The “beneficial effect” of discussion might
simply be a self-fulfilling prophecy.
Two papers [17, 18] have looked at implementation
rates for MDT recommendations. In the study from
Plymouth [17] the implementation rate was 44/47
(93.6 %), the rate in the study from Bristol [18] was 137/
157 (87.3 %). The rate in our study, confining analysis to
patients surviving for at least six weeks, was 407/490
(83.1 %).
Our results suggest that much of the workload of
MDT meetings, as they are currently constituted, may
have little impact upon cancer-specific survival in pa-
tients with colorectal cancer. For the group of 386 pa-
tients with early disease, 66 % of all patients discussed,
the presence or absence of adequate MDT process had
no significant effect on survival. MDT discussion of all
new patients is an instrument of cultural change and has
helped to establish an environment in which equality of
access to a uniform standard of care is now considered
the norm. There may be more cost-effective ways to
maintain this new culture. Coordination of care is import-
ant [19] but does not necessarily require the full majesty
of an MDT meeting. Decision-support systems [20–22]
could easily be used outwith a formal MDT meeting. For
more complex problems, an asynchronous virtual MDT
[23] might offer a more flexible and less labour-intensive
approach than weekly face-to-face meetings.
Population-based screening may bring with it a new
set of problems – primarily related to pathological inter-
pretation of early disease [24]. In the future there may
be an increase in the number of patients with early dis-
ease who present complex problems requiring MDT
discussion [25]. This indicates the need for a flexible ap-
proach to the role, remit and constitution of the MDT.
It will not be easy to modify the role of the traditional
MDT. Assumptions concerning the value of this practice
are now firmly embedded in the procedures for assessing
the quality of cancer services: the Scottish Quality Per-
formance Indicator (QPI) sets a target of 95 % of new
patients with colorectal cancer being discussed at an
MDT [26]; the colorectal MDTs in England are assessed
against a set of 43 measures, all of which concern
process rather than outcome [27].
Conclusions
In summary, we conclude that: the MDT process is as-
sociated with, but not necessarily the cause of, improved
survival in patients with advanced or metastatic colorec-
tal cancer; neither discussion at an MDT, nor evidence
for an implemented recommendation, significantly af-
fects survival in the 66 % of patients who present with
early or localised disease; much of the time currently
spent in MDT discussion may be futile, a more focussed
approach to discussion might represent better value for
money; in common with others [16, 17] we believe that
we should now reconsider the value of routine discus-
sion in an MDT meeting of all newly diagnosed patients
with colorectal cancer.
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